FDA grants fast track status to Terns’s FXR agonist to treat NASH

This article was originally published here

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, which is associated

The post FDA grants fast track status to Terns’s FXR agonist to treat NASH appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply